References
- Beaussant Y, Tulsky J, Guérin B, Schwarz-Plaschg C, Sanders JJ. Radcliffe Institute for Advanced Study Working Group on Psychedelic Research in Serious Illness. Mapping an Agenda for Psychedelic-Assisted Therapy Research in Patients with Serious Illness. J Palliat Med 2021 Apr 13. doi:https://doi.org/10.1089/jpm.2020.0764.
- Nutt D, Carhart-Harris R. The Current Status of Psychedelics in Psychiatry. JAMA Psychiatry 2021 Feb 1;78(2):121–122. doi:https://doi.org/10.1001/jamapsychiatry.2020.2171. PMID: 32725172.
- Dyck E. Psychedelics and Dying Care: A Historical Look at the Relationship between Psychedelics and Palliative Care. J Psychoactive Drugs 2019 Apr-Jun;51(2):102–107. doi:https://doi.org/10.1080/02791072.2019.1581308.
- Oram, M. The trials of psychedelic therapy: LSD psychotherapy in America. Baltimore: Johns Hopkins University Press; 2018.
- Reiche S, Hermle L, Gutwinski S, Jungaberle H, Gasser P, Majić T. Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: A systematic review. Prog Neuropsychopharmacol Biol Psychiatry 2018 Feb 2;81:1–10. doi:https://doi.org/10.1016/j.pnpbp.2017.09.012.
- Ross S. Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress. Int Rev Psychiatry 2018 Aug;30(4):317–330. doi:https://doi.org/10.1080/09540261.2018.1482261.
- Nichols DE. Psychedelics. Pharmacol Rev 2016;68:264–355. [Erratum in: Pharmacol Rev 2016;68:356].
- Barrett FS, Griffiths RR. Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates. Curr Top Behav Neurosci 2018;36:393–430. doi:https://doi.org/10.1007/7854_2017_474.
- Garcia-Romeu A, Kersgaard B, Addy PH. Clinical applications of hallucinogens: A review. Exp Clin Psychopharmacol 2016;24:229–268. doi:https://doi.org/10.1037/pha0000084.
- Tupper KW, Wood E, Yensen R, Johnson MW. Psychedelic medicine: a re-emerging therapeutic paradigm. CMAJ 2015;187(14):1054–1059. doi:https://doi.org/10.1503/cmaj.141124.
- Carlini EA, Maia LO. Plant and Fungal hallucinogens as toxic and therapeutics agents. In: P Gopalakrishnakone, C Carlini, R Ligabue-Braun, (eds.) Plant Toxins. Toxinology. Dordrechtp: Springer; 2019. p. 1–44. doi:https://doi.org/10.1007/978-94-007-6728-7_6-2.
- Pahnke WN, Kurland AA, Goodman LE, Richards WA. LSD-assisted psychotherapy with terminal cancer patients. Curr Psychiatr Ther 1969;9:144–52.
- Grof S, Goodman LE, Richards WA, Kurland AA. LSD-Assisted Psychotherapy in Patients with Terminal Cancer. Int. Pharmacopsychiat 1973;8(3):129–144.
- Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstadt AL, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry 2011 Jan;68(1):71–8. doi:https://doi.org/10.1001/archgenpsychiatry.2010.116.
- Gasser P, Holstein D, Michel Y, Doblin R, Yazar-Klosinski B, Passie T, et al. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis 2014 Jul;202(7):513–20. doi:https://doi.org/10.1097/NMD.0000000000000113.
- Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol 2016 Dec;30(12):1181–1197. doi:https://doi.org/10.1177/0269881116675513.
- Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol 2016 Dec;30(12):1165–1180. doi:https://doi.org/10.1177/0269881116675512.
- Ross S, Agin-Liebes G, Lo S, Zeifman RJ, Ghazal L, Benville J, et al. Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer. ACS Pharmacol Transl Sci 2021 Mar 18;4(2):553–562. doi:https://doi.org/10.1021/acsptsci.1c00020.
- Anderson BT, Danforth A, Daroff R, Stauffer C, Ekman E, Agin-Liebes G, et al. Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study. EClinical Medicine 2020;27; doi:https://doi.org/10.1016/j.eclinm.2020.100538.
- Rosenbaum D, Boyle AB, Rosenblum AM, Ziai S, Chasen MR, Med MP. Psychedelics for psychological and existential distress in palliative and cancer care. Current oncology 2019;26(4):225–226. doi:https://doi.org/10.3747/co.26.5009.
- Bossis AP. Psilocybin, Spirituality, and Palliative Care: Research and Implications. Alternative and Complementary Therapies Feb 2021;27(1):14–17. doi:https://doi.org/10.1089/act.2020.29309.apb.
- Garcia AC M, Silva BD, da Silva LC O, Mills J. Self-compassion in Hospice and Palliative Care: A systematic integrative review. J Hospice Palliat Nurs 2021;23(2):145–54. doi:https://doi.org/10.1097/NJH.0000000000000727.
- Garcia ACM, Camargos Junior JB, Sarto KK, Silva Marcelo CAD, Paiva EMDC, Nogueira DA, et al. Quality of life, self-compassion and mindfulness in cancer patients undergoing chemotherapy: A cross-sectional study. Eur J Oncol Nurs 2021 Apr;51:101924), doi:https://doi.org/10.1016/j.ejon.2021.101924.
- Hasse J. Psychedelics For Frontline Clinicians With Covid-Related Burnout? A Study Is Looking Into It. Forbes; 2021. Available from: https://www.forbes.com/sites/javierhasse/2021/06/08/psychedelics-for-frontline-clinicians-with-covid-related-burnout-a-study-is-looking-into-it/?sh=4dbef7147c22.
- Sansó N, Galiana L, Oliver A, Pascual A, Sinclair S, Benito E. Palliative Care Professionals’ Inner Life: Exploring the Relationships Among Awareness, Self-Care, and Compassion Satisfaction and Fatigue, Burnout, and Coping With Death. J Pain Symptom Manage 2015 Aug;50(2):200–7. doi:https://doi.org/10.1016/j.jpainsymman.2015.02.013. Epub 2015 Feb 18. PMID: 25701688.
- Mills J, Ramachenderan J, Chapman M, Greenland R, Agar M. Prioritising workforce wellbeing and resilience: What COVID-19 is reminding us about self-care and staff support. Palliat Med 2020;34(9):1137–1139. doi:https://doi.org/10.1177/0269216320947966.
- Beaussant Y, Sanders J, Sager Z, Tulsky JA, Braun IM, Blinderman CD, et al. Defining the Roles and Research Priorities for Psychedelic-Assisted Therapies in Patients with Serious Illness: Expert Clinicians’ and Investigators’ Perspectives. J Palliat Med 2020 Oct;23(10):1323–1334. doi:https://doi.org/10.1089/jpm.2019.0603.
- Barnett BS, Siu WO, Pope HG. A survey of American psychiatrists’ attitudes toward classic hallucinogens. J Nerv Ment Dis 2018;206:476–480.
- Anderson BT, Danforth AL, Grob CS. Psychedelic medicine: Safety and ethical concerns. Lancet Psychiatry 2020;7:829–830.
- Mills J, Rosenberg JP, Bollig G, Haberecht J. Last Aid and Public Health Palliative Care: Towards the development of personal skills and strengthened community action. Prog Palliat Care 2020;28(6):343–345. doi:https://doi.org/10.1080/09699260.2020.1829798.
- O’Connor M. Reflecting on suffering at the end-of-life. Prog Palliat Care 2021;29(1):1–4. doi:https://doi.org/10.1080/09699260.2021.1852470.